| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8721656 | Diabetes & Metabolism | 2017 | 8 Pages |
Abstract
These findings suggest that DPP-4 inhibitors can increase the risk of arthralgia. Thus, the benefits of glycaemic control must be weighed against the risk of arthralgia when prescribing DPP-4 inhibitors. Further studies are now needed to identify and confirm these risk factors.
Keywords
FDAIDFGLP-1GIPDPP-4MedDRARCTsarthralgiaRheumatoid arthritisRandomized controlled trialsInternational Diabetes FederationDipeptidyl peptidase-4Medical Dictionary for Regulatory ActivitiesFood and Drug AdministrationMeta-analysisSystematic reviewDipeptidyl peptidase-4 inhibitorsglucagon-like peptide-1glucose-dependent insulinotropic peptide
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
P. Men, N. He, C. Song, S. Zhai,